Treatment of Benign Prostatic Hyperplasia and Chronic Nonbacterial Prostatitis with Prostat

DH Yao, Y Jiang, YJ Ma

Shanghai Male Disease Medical Consultation and Service Center, Shanghai, People's Republic of China

One hundred nineteen patients ages 45- to 81 years old, diagnosed with benign prostatic hyperplasia (BPH) and 19 patients ages 21- to 45 years old with chronic nonbacterial prostatitis were treated with Prostat for a period of 3 months. Each patient was given two tablets orally per day, one in the morning and one in the evening. Each tablet contained 70 mg P5 pollen extract and 4 mg EA10 pollen extract. For the patients with BPH, the clinical effectiveness was evaluated according to the improvement in the following factors: I-PSS, residual urine volume, the maximum urine flow rate (MFR), the average urine flow rate, the size of the prostate as measured by DRE and ultrasound scan, and PSA. The results of the patients with chronic nonbacterial prostatitis were rated by the improvement in l-PSS, prostate pain, and massage-expressed prostatic secretion. At the end of the clinical trial, in the BPH group, 32.8% of the patients were judged greatly improved, 48.7% moderately improved, and 18.5% unchanged. The overall clinical effective rate was 81.5%. In the chronic nonbacterial prostatitis group, 21.10% of the patients improved greatly, 52.6% improved moderately, and 26.3% were judged unchanged. The total clinical effective rate was 73.7%. No adverse reactions were observed in either group.

In conclusion, these favorable results in the clinical trial confirmed that Prostat is an effective agent in the treatment of the symptoms of BPH and prostatitis. Further studies are necessary to elucidate the precise mode of action for the effective treatment of chronic nonbacterial prostatitis.